Publications

Recent papers.

A public record of the group’s work, newest first. This is not an exhaustive CV — see Prof Dube’s ORCID for the full list.

2025

2025

Immunomodulatory Nanoparticles Induce Autophagy in Macrophages and Reduce Mycobacterium tuberculosis Burden in the Lungs of Mice

Bekale, R.B., Maphasa, R.E., D’Souza, S., Hsu, N.J., Walters, A., Okugbeni, N., Kinnear, C., Jacobs, M., Sampson, S.L., Meyer, M., Morse, G.D. and Dube, A.

ACS Infectious Diseases, 11(3), 610–625.
2025

Vitamin D3 loaded polycaprolactone nanoparticles enhance the expression of the antimicrobial peptide cathelicidin in macrophages

Dlozi, P.N., Ahmed, R., Khoza, S. and Dube, A.

Artificial Cells, Nanomedicine, and Biotechnology, 53(1), 207–219.
2025

Formulation and clinical translation of inhalable nanomedicines for the treatment and prevention of pulmonary infectious diseases

Ahmed, R., Tewes, F., Aucamp, M. and Dube, A.

Drug Delivery and Translational Research.
2025

Nanomedicine Solutions for Alzheimer’s Disease: A Critical Review of Therapeutic Nanoparticle Strategies

Tutubala, T.E., Egunlusi, A.O., Fisher, D., Dube, A. and Joubert, J.

ACS Omega.
2025

Curcumin and curcumin-loaded poly(caprolactone) nanoparticles restore mitochondrial function in an in vitro Parkinson’s disease model

Buck, A.C., Smith, L., Dube, A., Bardien, S. and Maarman, G.J.

Phytomedicine Plus, 100893.
2025

Targeting myeloid cells with platelet-derived extracellular vesicles to overcome resistance of immune checkpoint blockade therapy

Yao, C., Ma, Q., Wang, H., Wu, B., Dai, H., Xu, J., Bai, J., Xu, F., Dube, A. and Wang, C.

Biomaterials, 321, 123336.
2025

Advanced Therapeutic Technologies for Malaria, Tuberculosis, HIV Infection and Neglected Tropical Diseases

Dube, A., Laverty, G. and Balogun, M.

Advanced Therapeutics, 2500115.
2025

Mitochondria targeted nanoparticles for the treatment of mitochondrial dysfunction-associated brain disorders

Buck, A.C., Maarman, G.J., Dube, A. and Bardien, S.

Frontiers in Bioengineering and Biotechnology, 13, 1563701.
2025

Synthesis of immunomodulatory biomimetic lipid polymer hybrid nanoparticles and application of zebrafish larvae in immunomodulation screening

Irabin, A.F., Ollewagen, T., Smith, C., Ahmed, R., Reineke, J., Reijnders, R., Sampson, S.L., du Plessis, N. and Dube, A.

European Journal of Pharmaceutical Sciences, 207, 107037.

2024

2024

Clinically Relevant Metallic Nanoparticles in Tuberculosis Diagnosis and Therapy

Akinnawo, C.A. and Dube, A.

Advanced Therapeutics, 2400189.
2024

Inhalational Delivery of β-glucan-chitosan-poly(lactic co-glycolic) acid Nanoparticles Enhance Alveolar Macrophage Rifampin Concentrations for the Treatment of Tuberculosis

Kutscher, H.L., Tamblin, M., Karki, S., Chaves, L., Baird, M., Parvin, A., Smith, E., Dube, A., Zhang, Z., Chakraborty, S. and Kenney, P.

Advanced Therapeutics, 2400057.
2024

Selenium Nanoparticle Activity against S. mutans Biofilms as a Potential Treatment Alternative for Periodontitis

Hamman, N., Ramburrun, P. and Dube, A.

Pharmaceutics, 16(4), 450.

2023

2023

Nanophytomedicines as Therapeutic Agents for Parkinson’s Disease

Burns, J., Buck, A.C., D’Souza, S., Dube, A. and Bardien, S.

ACS Omega, 8(45), 42045–42061.
2023

Situation analysis on the regulation of nanomedicines in Southern Africa

Mudyiwenyama, L., Khoza, S. and Dube, A.

Frontiers in Medicine, 10, 1098830.

2015–2022

Archive

Physicochemical and biological evaluation of curdlan-poly(lactic-co-glycolic acid) nanoparticles as a host-directed therapy against Mycobacterium tuberculosis

D'Souza, S., Du Plessis, S.M., Egieyeh, S., Bekale, R.B., Maphasa, R.E., Irabin, A.F., Sampson, S.L. and Dube, A.

Journal of Pharmaceutical Sciences, 111(2), 469–478. · 2022
Archive

The Macrophage Response to Mycobacterium tuberculosis and Opportunities for Autophagy Inducing Nanomedicines for Tuberculosis Therapy

Maphasa, R.E., Meyer, M. and Dube, A.

Frontiers in Cellular and Infection Microbiology, 10, 618414. · 2021
Archive

Nanomedicines for Infectious Diseases

Dube, A.

Pharmaceutical Research, 36(4), 63. · 2019
Archive

Curdlan-Conjugated PLGA Nanoparticles Possess Macrophage Stimulant Activity and Drug Delivery Capabilities

Tukulula, M., Hayeshi, R., Fonteh, P., Meyer, D., Ndamase, A., Madziva, M.T., Khumalo, V., Lubuschagne, P., Naicker, B., Swai, H. and Dube, A.

Pharmaceutical Research, 32(8), 2713–2726. · 2015

Earlier papers — including work on malaria nanoformulations, PEGylated PLGA, pentamidine BBB transport, and the South African nanomedicine landscape — are listed in Prof Dube’s ORCID record.

ORCID 0000-0002-5684-6094